London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, is pleased to announce today the signature of a lease for
ValiRx PLC (AIM:VAL) Launch of Broker Offer to raise a maximum of £500,000
Launch of Broker Offer to raise a maximum of £500,000
ValiRx PLC (AIM:VAL) Quarterly Operational and Strategy Update
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, today provides an update on operational activities and strategy.
ValiRx PLC (AIM:VAL) Live Shareholder Q&A and industry events
Live Q&A: London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, invites shareholders to join the CEO, Suzy Dilly and
ValiRx PLC (AIM:VAL) Successful evaluation of breast cancer programme
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, is pleased to announce that the project subject to the Evaluation
ValiRx PLC (AIM:VAL) Update on VAL201 sub-license agreement
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, is today providing an update on its proposed sub-license agreement with
ValiRx PLC (AIM:VAL) Update on proposed sub-license of VAL201
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health today provides an update on progress towards the completion of the
ValiRx PLC (AIM:VAL) Operational and Strategy Update
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, today provides an update on operational activities and strategy.
ValiRx PLC (VAL.L) VAL201 Clinical Trial Full Data Results
Full dataset confirms VAL201 is a safe and well-tolerated drug candidate
ValiRx Plc (VAL.L) October Q&A 2020
CEO introduction
ValiRx PLC (VAL.L) VAL201 Clinical Trial Update
Headline results demonstrate VAL201 has potential to be a safe and well-tolerated drug